Expectations trend
FY2028 · fiscal year ending 2028-03-31 · fmp
AETHLON MEDICAL INC (AEMD)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$5.31-7.65%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for AEMD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce negative cash from operations toward negative $1.75M | Aethlon Medical aims to reduce losses and improve cash flow. | Broken | cash from operations worsens beyond negative $1.75M in 2026-Q4 | Cash from operations: $-1.897B FY2027-Q1; GAAP. Published target: >= -1.75 million USD cash from operations. The stored target says 2026-Q4; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Aug 13, 2026-1,896,539,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-03-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
AEMD is a speculative clinical-stage healthcare company, not an established earnings compounder. Its multi-year thesis is in a watch state: management has advanced the oncology study, but the company remains loss-making and overall risk is high.
The valuation model indicates AEMD trades at a premium to peers, while its confidence is low and the expectations gap is large. The evidence points to optionality, meaning value tied to possible future clinical progress, as a key part of the case; the snapshot does not provide enough detail to say exactly what clinical outcomes the market assumes.
Near term, the company has shown progress on its stated priorities: the Phase 1 oncology study reached its final dosing cohort, and quarterly operating expenses fell year over year. It still reports no revenue, has raised capital to support operations, and faces a meaningful risk of an erratic next earnings result; recent performance also sits below its industry cohort.
Over the multi-year view, the thesis hinges on continued progress in Hemopurifier clinical trials and whether expense control and funding can sustain operations. Near-term sector signals could also matter: continued strength from healthcare bellwethers may support the sector backdrop, while weaker jobs data or missed guidance from those companies could add pressure.
AEMD's long-term thesis remains uncertain: clinical progress and lower expenses are constructive, but losses, financing needs, high risk, and weak relative performance keep the evidence mixed. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Reduce operating losses toward negative $1.5M or better |
| Operating loss improved from negative $2.9M to negative $1.5M in 2026-Q2. |
| Broken |
| operating loss worsens beyond negative $1.5M in 2026-Q2 |
Operating income: $-1.579M FY2027-Q1; GAAP. Published target: >= -1.5 million USD operating loss. The stored target says 2026-Q2; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Aug 13, 2026-1,579,202 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve about 71% revenue growth | A supporting condition in AETHLON MEDICAL INC's published investment case. The stated target is >= 71% YoY revenue growth. | Intact | revenue growth falls below 50% next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.50 → $-1.91 · observed estimates
$0.00B → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.50 | $0 | 1 / 2 |
| 2026-07-25 | $-0.50 | $0 | 1 / 2 |
| 2026-07-26 | $-1.80 | Unavailable | 1 / 0 |
| 2026-07-27 | $-1.80 | Unavailable | 1 / 0 |
| 2026-07-28 | $-1.80 | Unavailable | 1 / 0 |
| 2026-07-29 | $-0.50 | $0 | 1 / 2 |
| 2026-07-30 | $-0.50 | $0 | 1 / 2 |
| 2026-07-31 | $-0.50 | $0 | 1 / 2 |
| 2026-08-01 | $-0.50 | $0 | 1 / 2 |
| 2026-08-02 | $-0.50 | $0 | 1 / 2 |
| 2026-08-03 | $-0.50 | $0 | 1 / 2 |
| 2026-08-04 | $-0.50 | $0 | 1 / 2 |
| 2026-08-05 | $-2.50 | $0 | 1 / 2 |
| 2026-08-06 | $-2.50 | $0 | 1 / 2 |
| 2026-08-07 | $-2.50 | $0 | 1 / 2 |
| 2026-08-08 | $-2.50 | $0 | 1 / 2 |
| 2026-08-09 | $-2.50 | $0 | 1 / 2 |
| 2026-08-10 | $-2.50 | $0 | 1 / 2 |
| 2026-08-11 | $-2.50 | $0 | 1 / 2 |
| 2026-08-12 | $-2.50 | $0 | 1 / 2 |
| 2026-08-13 | $-1.80 | Unavailable | 1 / 0 |
| 2026-08-14 | $-1.80 | Unavailable | 1 / 0 |
| 2026-08-15 | $-1.80 | Unavailable | 1 / 0 |
| 2026-08-16 | $-1.80 | Unavailable | 1 / 0 |
| 2026-08-17 | $-1.80 | Unavailable | 1 / 0 |
| 2026-08-18 | $-1.80 | Unavailable | 1 / 0 |
| 2026-08-19 | $-1.80 | Unavailable | 1 / 0 |
| 2026-08-20 | $-1.80 | Unavailable | 1 / 0 |
| 2026-08-21 | $-1.91 | Unavailable | 1 / 0 |
| 2026-08-22 | $-1.91 | Unavailable | 1 / 0 |
| 2026-08-23 | $-1.91 | Unavailable | 1 / 0 |
| 2026-08-24 | $-1.91 | Unavailable | 1 / 0 |
| 2026-08-25 | $-1.91 | Unavailable | 1 / 0 |
| 2026-08-26 | $-1.91 | Unavailable | 1 / 0 |
| 2026-08-27 | $-1.91 | Unavailable | 1 / 0 |
| 2026-08-28 | $-1.91 | Unavailable | 1 / 0 |
| 2026-08-29 | $-1.91 | Unavailable | 1 / 0 |
| 2026-08-30 | $-1.91 | Unavailable | 1 / 0 |
| 2026-08-31 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-01 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-02 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-03 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-04 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-05 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-06 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-07 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-08 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-09 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-10 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-11 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-12 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-13 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-14 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-15 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-16 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-17 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-18 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-19 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-20 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-21 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-22 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-23 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-24 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-25 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-26 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-27 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-28 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-29 | $-1.91 | Unavailable | 1 / 0 |
| 2026-09-30 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-01 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-02 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-03 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-04 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-05 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-06 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-07 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-08 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-09 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-10 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-11 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-12 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-13 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-14 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-15 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-16 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-17 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-18 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-19 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-20 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-21 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-22 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-23 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-24 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-25 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-26 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-27 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-28 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-29 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-30 | $-1.91 | Unavailable | 1 / 0 |
| 2026-10-31 | $-1.91 | Unavailable | 1 / 0 |
| 2026-11-01 | $-1.91 | Unavailable | 1 / 0 |
| 2026-11-02 | $-1.91 | Unavailable | 1 / 0 |
| 2026-11-03 | $-1.91 | Unavailable | 1 / 0 |
| 2026-11-04 | $-1.91 | Unavailable | 1 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.